Melatonin as a preventive and curative therapy against pulmonary hypertension

Journal of Pineal Research

Volumn 59, Issue 3, 2015, Pages 343-353

  Maarman, Gerald ^a   Blackhurst, Dee ^b   Thienemann, Friedrich ^b   Blauwet, Lori ^c   Butrous, Ghazwan ^d   Davies, Neil ^b   Sliwa, Karen ^a   Lecour, Sandrine ^a  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

cardioprotection; melatonin; monocrotaline; oxidative stress; pulmonary hypertension

Indexed keywords

CATALASE; MELATONIN; MONOCROTALINE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROSING ALVEOLITIS; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOLOGY; LIVER WEIGHT; LONG TERM CARE; LUNG WEIGHT; MALE; NONHUMAN; ORAC ASSAY; OXIDATIVE STRESS; PROPHYLAXIS; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; CHEMICALLY INDUCED; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LONG EVANS RAT; PREVENTION AND CONTROL;

ANIMALS; ANTIOXIDANTS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MELATONIN; MONOCROTALINE; RATS; RATS, LONG-EVANS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84942191195     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12263     Document Type: Article

References (65)

1. Badesch DB, Raskob GE, Elliott CG, et al., Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
2. Simonneau G, Robbins IM, Beghetti M, et al., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
3. Galie N, Hoeper MM, Humbert M, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
4. Minai OA, Chaouat A, Adnot S,. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010; 137: 39S-51S.
5. Voelkel NF, Gomez-Arroyo J, Abbate A, et al., Mechanisms of right heart failure-A work in progress and a plea for failure prevention. Pulm Circ 2013; 3: 137-143.
6. Vonk-Noordegraaf A, Haddad F, Chin KM, et al., Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013; 62: D22-D33.
7. Bogaard HJ, Abe K, Vonk Noordegraaf A, et al., The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135: 794-804.
8. Bogaard HJ, Mizuno S, Hussaini AA, et al., Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011; 183: 1402-1410.
9. Rich S,. Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension. Cardiol Clin 2012; 30: 257-269.
10. Gomberg-Maitland M, Dufton C, Oudiz RJ, et al., Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol 2011; 57: 1053-1061.
11. Gabler NB, French B, Strom BL, et al., Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141: 20-26.
12. Rich S, Pogoriler J, Husain AN, et al., Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010; 138: 1234-1239.
13. Wong CM, Bansal G, Pavlickova L, et al., Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal 2013; 18: 1789-1796.
14. Voelkel NF, Quaife RA, Leinwand LA, et al., Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
15. Handoko ML, de Man FS, Allaart CP, et al., Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur Respir Rev 2010; 19: 72-82.
16. Ventetuolo CE, Klinger JR,. WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Prog Cardiovasc Dis 2012; 55: 89-103.
17. Masri FA, Comhair SA, Dostanic-Larson I, et al., Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clin Transl Sci 2008; 1: 99-106.
18. Joppa P, Petrasova D, Stancak B, et al., Oxidative stress in patients with COPD and pulmonary hypertension. Wien Klin Wochenschr 2007; 119: 428-434.
19. Bowers R, Cool C, Murphy RC, et al., Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004; 169: 764-769.
20. Mohammadi S, Najafi M, Hamzeiy H, et al., Protective effects of methylsulfonylmethane on hemodynamics and oxidative stress in monocrotaline-induced pulmonary hypertensive rats. Adv Pharmacol Sci 2012; 2012: 507278.
21. Dorfmuller P, Chaumais MC, Giannakouli M, et al., Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res 2011; 12: 119.
22. Leichsenring-Silva F, Tavares AM, Mosele F, et al., Association of the time course of pulmonary arterial hypertension with changes in oxidative stress in the left ventricle. Clin Exp Pharmacol Physiol 2011; 38: 804-810.
23. Redout EM, van der Toorn A, Zuidwijk MJ, et al., Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 2010; 298: H1038-H1047.
24. Tengattini S, Reiter RJ, Tan DX, et al., Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16-25.
25. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ,. Cardioprotection and pharmacological therapies in acute myocardial infarction: challenges in the current era. World J Cardiol 2014; 6: 100-106.
26. Simko F, Paulis L,. Antifibrotic effect of melatonin-perspective protection in hypertensive heart disease. Int J Cardiol 2013; 168: 2876-2877.
27. Simko F, Bednarova KR, Krajcirovicova K, et al., Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. J Pineal Res 2014; 57: 177-184.
28. Yang Y, Sun Y, Yi W, et al., A review of melatonin as a suitable antioxidant against myocardial ischemia-reperfusion injury and clinical heart diseases. J Pineal Res 2014; 57: 357-366.
29. Tan DX, Zanghi BM, Manchester LC, et al., Melatonin identified in meats and other food stuffs: potentially nutritional impact. J Pineal Res 2014; 57: 213-218.
30. Tan DX, Hardeland R, Manchester LC, et al., Emergence of naturally occurring melatonin isomers and their proposed nomenclature. J Pineal Res 2012; 53: 113-121.
31. Konturek SJ, Konturek PC, Brzozowski T, et al., Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol 2007; 58 (Suppl 6): 23-52.
32. Reiter RJ, Tan DX, Mayo JC, et al., Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
33. Reiter RJ, Manchester LC, Fuentes-Broto L, et al., Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens 2010; 28 (Suppl 1): S7-S12.
34. Reiter RJ, Tan DX, Galano A,. Melatonin: exceeding expectations. Physiology (Bethesda) 2014; 29: 325-333.
35. Gringras P, Gamble C, Jones AP, et al., Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012; 345: e6664.
36. El-Missiry MA, Abd El-Aziz AF,. Influence of melatonin on proliferation and antioxidant system in Ehrlich ascites carcinoma cells. Cancer Lett 2000; 151: 119-125.
37. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al., Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 2008; 199: 73-78.
38. Lamont KT, Somers S, Lacerda L, et al., Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 2011; 50: 374-380.
39. Nduhirabandi F, Du Toit EF, Blackhurst D, et al., Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res 2011; 50: 171-182.
40. Jin H, Wang Y, Zhou L, et al., Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells. J Pineal Res 2014; 57: 442-450.
41. Torres F, Gonzalez-Candia A, Montt C, et al., Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep. J Pineal Res 2015; 58: 310-320.
42. Xu MF, Ho S, Qian ZM, et al., Melatonin protects against cardiac toxicity of doxorubicin in rat. J Pineal Res 2001; 31: 301-307.
43. Lecour S, Smith RM, Woodward B, et al., Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-518.
44. Jentzsch AM, Bachmann H, Furst P, et al., Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996; 20: 251-256.
45. Blackhurst DM, Marais AD,. Concomitant consumption of red wine and polyunsaturated fatty acids in edible oil does not influence the peroxidation status of chylomicron lipids despite increasing plasma catechin concentration. Nutr Metab Cardiovasc Dis 2006; 16: 550-558.
46. Dalloz F, Maingon P, Cottin Y, et al., Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med 1999; 26: 785-800.
47. Lecour S, Owira P, Opie LH,. Ceramide-induced preconditioning involves reactive oxygen species. Life Sci 2006; 78: 1702-1706.
48. Kosanovic D, Kojonazarov B, Luitel H, et al., Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respir Res 2011; 12: 87.
49. Handoko ML, Lamberts RR, Redout EM, et al., Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol 2009; 297: H1752-H1759.
50. Hessel MH, Steendijk P, Den Adel B, et al., Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006; 291: H2424-H2430.
51. Maarman G, Lecour S, Butrous G, et al., A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ 2013; 3: 739-756.
52. Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al., The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012; 302: L363-L369.
53. Stones R, Benoist D, Peckham M, et al., Microtubule proliferation in right ventricular myocytes of rats with monocrotaline-induced pulmonary hypertension. J Mol Cell Cardiol 2013; 56: 91-96.
54. Hardziyenka M, Campian ME, Verkerk AO, et al., Electrophysiologic remodeling of the left ventricle in pressure overload-induced right ventricular failure. J Am Coll Cardiol 2012; 59: 2193-2202.
55. Tsutsui H, Kinugawa S, Matsushima S,. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011; 301: H2181-H2190.
56. Farber HW, Loscalzo J,. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
57. Demarco VG, Whaley-Connell AT, Sowers JR, et al., Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol 2010; 2: 316-324.
58. Reagan-Shaw S, Nihal M, Ahmad N,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
59. Rodriguez C, Mayo JC, Sainz RM, et al., Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
60. Venegas C, Garcia JA, Escames G, et al., Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52: 217-227.
61. Campian ME, Verberne HJ, Hardziyenka M, et al., Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med 2009; 50: 1371-1377.
62. Ersahin M, Sehirli O, Toklu HZ, et al., Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res 2009; 47: 97-106.
63. Piechota A, Lipinska S, Szemraj J, et al., Long-term melatonin administration enhances the antioxidant potential of human plasma maintained after discontinuation of the treatment. Gen Physiol Biophys 2010; 29: 144-150.
64. Scheer FA, van Montfrans GA, van Someren EJ, et al., Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-197.
65. Grossman E, Laudon M, Yalcin R, et al., Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006; 119: 898-902.